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Background. Several consensus groups have previously published operational criteria for sarcopenia, incorporat-
ing lean mass with strength and/or physical performance. The purpose of this manuscript is to describe the prevalence, 
agreement, and discrepancies between the Foundation for the National Institutes of Health (FNIH) criteria with other 
operational definitions for sarcopenia.
Methods. The FNIH Sarcopenia Project used data from nine studies including: Age, Gene and Environment 
Susceptibility-Reykjavik Study; Boston Puerto Rican Health Study; a series of six clinical trials from the University of 
Connecticut; Framingham Heart Study; Health, Aging, and Body Composition Study; Invecchiare in Chianti; Osteoporotic 
Fractures in Men Study; Rancho Bernardo Study; and Study of Osteoporotic Fractures. Participants included in these anal-
yses were aged 65 and older and had measures of body mass index, appendicular lean mass, grip strength, and gait speed.
Results.  The prevalence of sarcopenia and agreement proportions was higher in women than men. The lowest preva-
lence was observed with the FNIH criteria (1.3% men and 2.3% women) compared with the International Working 
Group and the European Working Group for Sarcopenia in Older Persons (5.1% and 5.3% in men and 11.8% and 13.3% 
in women, respectively). The positive percent agreements between the FNIH criteria and other criteria were low, rang-
ing from 7% to 32% in men and 5% to 19% in women. However, the negative percent agreement were high (all >95%).
Conclusions.  The FNIH criteria result in a more conservative operational definition of sarcopenia, and the prevalence 
was lower compared with other proposed criteria. Agreement for diagnosing sarcopenia was low, but agreement for rul-
ing out sarcopenia was very high. Consensus on the operational criteria for the diagnosis of sarcopenia is much needed 
to characterize populations for study and to identify adults for treatment.
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L
OW muscle mass and weakness are potential 
  contributors to disability in older persons. Although the 
term “sarcopenia” has become widespread, the criteria for 
an operational definition vary among studies and experts. 
Initial work on defining sarcopenia was based on measures 
of muscle mass alone, and the prevalence of sarcopenia 
when compared with a young reference population ranged 
between 13% and 24% among adults younger than 70 years 
to more than 50% among adults older than 80 years (1). 
However, a growing body of research suggests that there 
is a disconnect between muscle mass and strength. Thus, 
recent definitions of sarcopenia have incorporated elements   OPERAtIONAL CRItERIA FOR thE PRESENCE OF SARCOPENIA  585
of strength and physical performance in addition to muscle 
mass in the criteria for sarcopenia (2–5). However, these 
consensus statements were based on expert opinions and 
lacked access to large data sets to validate their recommen-
dations. Thus, the goal of the Foundation for the National 
Institutes of Health (FNIH) Sarcopenia Project was to cre-
ate a data-driven set of criteria for clinically relevant weak-
ness and low lean mass using pooled data from multiple 
studies.
This is the fifth report of the FNIH Sarcopenia Project. 
The first manuscript describes the rationale for the FNIH 
Sarcopenia Project and characteristics of the participating 
studies. The second and third manuscripts describe in detail 
the development of cutpoints for weakness and low lean 
mass; and the fourth manuscript demonstrates the predic-
tive validity of these cutpoints. The purpose of the analyses 
presented here is to compare the criteria developed by the 
FNIH project to other published criteria, in order to assess 
prevalence, agreement, and discrepancies between candi-
date criteria. Our goal is to provide data-driven evidence to 
the field in order to advance professional consensus regard-
ing clinically relevant cutpoints and terminology.
Methods
Participants
The studies participating in the FNIH Sarcopenia Project 
are described in the first manuscript in this series (6). 
They include: Age, Gene and Environment Susceptibility-
Reykjavik Study (AGES) (7); Boston Puerto Rican Health 
Study (BPRHS) (8); six clinical trials at University of 
Connecticut (UCONN) (9–14); Framingham Heart Study 
(FHS) Original cohort (15) and the Offspring cohort (16); 
Health, Aging, and Body Composition Study (HABC) 
(17); Invecchiare in Chianti (InChianti) (18); Osteoporotic 
Fractures in Men Study (MrOS) (19,20); Rancho Bernardo 
Study (RBS) (21); and Study of Osteoporotic Fractures 
(SOF) (22,23). To be included in these analyses, partici-
pants must be aged 65 and older and must have completed, 
at a single time point, the following measures: objectively 
measured body mass index (BMI), appendicular lean 
mass (ALM: sum of lean mass in the arms and legs), grip 
strength, and gait speed. Participants from RBS and AGES 
were excluded because RBS did not measure walking speed 
and AGES measured body composition with bioelectrical 
impedance (BIA). A total of 7,113 men and 2,950 women 
were included in the analyses presented here.
Measurement of Lean Mass, Strength, and Performance
Gait speed was measured as the length of the walking 
course (4 or 6 m) divided by the time it took participants 
to walk the course at their usual pace. Walking courses that 
were longer or shorter were converted to a speed that would 
have been achieved on a 4- or 6-m course using previously 
published equations (24). If more than one test was admin-
istered, the average gait speed (m/s) was used. Grip strength 
was measured by a handheld dynamometer, and the maxi-
mum value of either hand was analyzed. Total body fat mass 
and total bone-free lean mass (kg) were acquired using dual 
energy x-ray absorptiometry (DXA) on Hologic (Waltham, 
MA) or Lunar/GE Healthcare (Madison, WI) machines.
Operational Definitions of Lean Mass, Strength, and 
Other Factors
The FNIH cutpoints for grip strength and lean mass, 
derived from classification and regression tree analysis, were 
reported in two accompanying articles (25,26). Participants 
with gait speed less than or equal to 0.8 m/s were classified 
as having slow walking speed. Men with grip strength less 
than 26 kg and women with a grip strength less than 16 kg 
were defined as weak (25). We used ALM divided by body 
size (ALMBMI) to determine lean mass; men with ALMBMI 
less than 0.789 and women with ALMBMI less than 0.512 
were classified as low lean mass (26). We also examined 
our alternative definitions for low lean mass using absolute 
ALM (not corrected for body size); men with ALM less 
than 19.75 kg and women with ALM less than 15.02 were 
classified as low lean mass (data not shown). Using these 
cutpoints, we examined two possible FNIH definitions: (i) 
clinically relevant weakness and low lean mass (low grip 
strength + low ALMBMI) or (ii) clinically relevant slowness 
with weakness and low lean mass (slow gait speed + low 
grip strength + low ALMBMI). These definitions were used 
to compare with other proposed definitions for sarcopenia.
Several groups have previously published operational 
criteria to define sarcopenia, including: (i) International 
Working Group (IWG) (4); (ii) European Working Group 
on Sarcopenia Older Persons (EWGSOP) (3); (iii) European 
Society for Clinical Nutrition and Metabolism Special 
Interest Group on cachexia-anorexia in chronic wasting 
diseases (ESPEN) (2); and (iv) Society of Sarcopenia, 
Cachexia, and Wasting Disorders (SCWD) (5). These rec-
ommendations combined lean mass with a strength and/or 
physical performance measure. The EWGSOP suggested 
that sarcopenia be defined as low lean mass + low strength 
and/or low performance. The EWGSOP differentiated pre-
sarcopenia (low mass) from sarcopenia (low mass + low 
strength or low performance) and severe sarcopenia (low 
mass + low strength + low performance). Several pos-
sible performance measures (grip strength, chair stand, 
gait speed), lean mass assessment methods (DXA, bioim-
pedance, computed tomography, and magnetic resonance 
imaging), and different cutpoints were suggested by the 
EWGSOP. For the FNIH analyses, we used ALM by DXA, 
grip strength, and gait speed as measures of muscle mass, 
strength, and physical performance (3) and used similar 
cutpoints that were recently published to operationalize the 
EWGSOP criteria (27–29). The IWG recommended gait 586  DAM Et AL.
speed as a measure of physical performance and defined 
gait speed less than 1 m/s as slow (4). The recommenda-
tions for ESPEN and SCWD were similar to EWGSOP and 
IWG, thus were not analyzed separately. The operational 
cutpoints used in these analyses are summarized in Table 1.
Statistical Analysis
Data were analyzed for men and women separately. 
Descriptive statistics were examined across sets of criteria. 
Sensitivity and specificity were not determined because 
they are not applicable in the absence of a gold standard 
criterion to define sarcopenia. Furthermore, positive pre-
dictive value, negative predictive value, and likelihood 
ratios cannot be computed because a participant’s sta-
tus (as determined by a reference standard) is unknown. 
Therefore, we described the agreement between the FNIH 
criteria with other proposed criteria using several differ-
ent statistical measures (30), including: (i) positive percent 
agreement: the proportion of participants who were cat-
egorized as having the condition by both the FNIH criteria 
and a second set of criteria divided by the number of par-
ticipants who were categorized as having the condition by 
the second set of criteria. This is analogous to a sensitivity 
calculation; (ii) negative percent agreement: the propor-
tion of participants who were categorized as not having the 
condition by both the FNIH criteria and a second set of 
criteria divided by the number of participants who were 
categorized as not having the condition by the second set of 
criteria. This is analogous to a specificity calculation; and 
(iii) Cohen’s kappa (κ). Kappa (κ) values less than 0.40 are 
considered poor reliability, 0.40–0.75 are considered fair-
to-good reliability, and greater than 0.75 are considered 
excellent reliability (30).
Results
These analyses included 10,063 participants (7,113 
men and 2,950 women). Mean ± SD for gait speeds were 
1.23  ±  0.24 m/s and 0.97  ±  0.24 m/s; grip strengths were 
40.7 ± 8.8 kg  and  21.1 ± 5.9 kg;  ALMBMI  were  0.88 ± 0.11 
kg and 0.60  ±  0.10  kg; and ALM were 40.23  ±  8.92 kg and 
20.58 ± 5.81 kg, for men and women, respectively. The pro-
portion of participants who fell below the FNIH cutpoints 
for gait speed, grip strength, lean mass, and the multiple 
combinations are presented in Figure 1. Compared with 
ALM divided by height squared (ALM/ht2), participants 
with low lean mass by the FNIH criteria (ALMBMI) were 
heavier with higher BMI and ALM; more participants were 
overweight or obese and reported a history of diabetes and 
heart failure (Supplementary Table 1). Despite their larger 
body size, adults with low lean mass by the FNIH ALMBMI 
cutpoint had poorer physical function including weaker 
grip strength, slower mean walking speed, and a higher per-
centage with walking speed less than or equal to 0.8 m/s 
compared with participants with low lean mass defined by 
ALM/ht2.
The various proposed operational definitions and prev-
alence of sarcopenia are presented in Table 1. Note that 
primary indicator of lean mass for the FNIH project was 
ALMBMI, whereas all other proposed criteria used ALM/
ht2. These sets of candidate definitions largely differed from 
Table 1.  Summary of Operational Definitions for Sarcopenia and Prevalence by Gender
Criteria
Operational Definition Prevalence (%)
Physical 
Performance
Muscle 
Strength ALM
Men 
(n = 7,113)
Women 
(n = 2,950)
Foundation of NIH Sarcopenia Project
Weakness and low lean mass — Grip strength ALMBMI 1.3 2.3
Men: <26 kg   Men: <0.789
Women: <16 kg   Women: <0.512
Slowness with weakness 
and low lean mass
Gait speed: ≤0.8 m/s Grip strength ALMBMI 0.5 1.8
Men: <26 kg   Men: <0.789
Women: <16 kg   Women: <0.512
International Working 
Group
Gait speed: <1.0 m/s — ALM/ht2 5.1 11.8
  Men: ≤7.23 kg/m2
  Women: ≤5.67 kg/m2
European Working Group on Sarcopenia Older Persons
Sarcopenia Gait speed: <0.8 m/s or ALM/ht2 5.3 13.3
Grip strength   Men: ≤7.23 kg/m2
  Men: <30 kg   Women: ≤5.67 kg/m2
  Women: <20 kg
Severe sarcopenia Gait speed: <0.8 m/s Grip strength ALM/ht2 0.7 2.9
  Men: <30 kg   Men: ≤7.23 kg/m2
  Women: <20 kg   Women: ≤5.67 kg/m2
Note: ALMBMI = ratio of appendicular lean mass over body mass index; ALM/ht2 = ratio of appendicular lean mass over height squared.  OPERAtIONAL CRItERIA FOR thE PRESENCE OF SARCOPENIA  587
each other in regards to the cutpoint for slow gait speed 
and whether or not to include a measure of weakness. The 
prevalence of sarcopenia was higher in women than men. In 
men, the prevalence was 1.3% for the FNIH criteria, 5.1% 
for IWG, and 5.3% for EWGSOP. In women, the preva-
lence was 2.3% for FNIH, 11.8% for IWG, and 13.3% for 
EWGSOP. When we included gait speed with grip strength 
and lean mass in the FNIH definition, the proportion of par-
ticipants who met all three was lower: 0.5% in men and 
1.8% in women. Furthermore, the prevalence of severe sar-
copenia by the EWGSOP was 0.7% in men and 2.9% in 
women. In general, the FNIH criteria, compared with other 
proposed definitions, identified participants who were older 
with higher BMI and higher lean mass, but were function-
ally more impaired, including a higher proportion with slow 
gait and inability to rise from a chair (Supplementary Tables 
2 and 3).
Table 2 presents agreement proportions between the vari-
ous criteria. In general, agreement was higher in men than 
in women and higher between the FNIH and EWGSOP cri-
teria. The positive percent agreements between the FNIH 
criteria and other criteria were low, ranging from 4.3% 
Table 2. Agreement Comparing the FNIH Criteria With Other Operational Criteria for Sarcopenia
IWG
EWGSOP 
Sarcopenia
EWGSOP 
Severe Sarcopenia
PPA (%) NPA (%) κ PPA (%) NPA (%) κ PPA (%) NPA (%) κ
Men
  FNIH weakness and low lean mass 9.0 98.5 0.14 19.1 99.1 0.53 32.0 98.3 0.23
FNIH slowness with weakness and  
low lean mass
7.1 99.7 0.11 4.3 99.7 0.07 32.0 99.7 0.17
Women
  FNIH weakness and low lean mass 9.0 97.8 0.12 11.4 96.8 0.14 18.9 97.0 0.17
FNIH slowness with weakness and  
low lean mass
4.5 99.6 0.04 4.0 98.5 0.04 19.9 99.7 0.17
Note: EWGSOP = European Working Group on Sarcopenia Older Persons; FNIH = Foundation of the National Institute of Health; IWG = International Working 
Group on Sarcopenia; NPA = negative percent agreement: the proportion of participants who were categorized as not having the condition by both the FNIH criteria 
and a second set of criteria divided by the number of participants who were categorized as not having the condition by the second set of criteria; PPA = positive percent 
agreement: the proportion of participants who were categorized as having the condition by both the FNIH criteria and a second set of criteria divided by the number 
of participants who were categorized as having the condition by the second set of criteria.
Figure 1.  Independence and overlap of prevalent FNIH criterion (slowness, weakness, and low lean mass) among men (n = 7,113) and women (n = 2,950) in the 
pooled data set. Descriptions of the criterion are described in Methods section. Numbers in the circle represent the percentage of the sample with each of these criteria. 
Numbers in the areas of overlap indicate the percentage of the sample that has more than criterion. Only 0.5% men and 1.8% women share all criteria.588  DAM Et AL.
to 32% in men and 4.0% to 19.9% in women. However, 
the negative percent agreement was very high (all >95%). 
Our results demonstrated that kappa values were modest, 
with a range of 0.11–0.53 in men and 0.04–0.17 in women. 
Between the IWG and EWGSOP definitions, the positive 
percent agreement for sarcopenia was 52.1% and 61.7% in 
men and women, respectively. The negative percent agree-
ment for sarcopenia was 97.1% and 96.4% in men and 
women, respectively.
Discussion
The prevalence of sarcopenia varies greatly depending 
on the criteria used for diagnosis. Based on the presence 
of lean mass alone, initial prevalence of sarcopenia ranged 
between 7% and 50%. The large range was due to differ-
ences in the criterion used to diagnose sarcopenia, including 
(i) definitions that only included lean mass with or with-
out correction for height (1,31), body mass (32), or body 
height and body fat (33); (ii) methodological differences to 
measure muscle mass (DXA or BIA) (1,32–35); and (iii) 
differences in the reference population used to establish 
normative data. In this study, the prevalence of sarcopenia 
incorporating both low lean mass and poor function were 
much lower—between 0.5% and 5.3% in men and 1.8% 
and 13.3% in women compared with definitions based on 
muscle mass alone.
When comparing the FNIH, EWGSOP, and IWG criteria 
in this pooled sample, the positive percent agreements were 
low, but the negative percent agreements were high (all 
>95%), suggesting that there was good agreement on the 
absence of the condition. The prevalence of sarcopenia was 
highest with the EWGSOP criteria in both men and women 
(5.3% and 13.3%, respectively). Given that the FNIH crite-
ria were more restrictive, it was not surprising that the prev-
alence of sarcopenia was lower than either the EWGSOP 
or IWG criteria. Adults considered sarcopenic by both the 
FNIH and EWGSOP or by both FNIH and IWG criteria had 
little overlap as evidenced by the modest positive percent 
agreement and kappa values. However, the FNIH criteria 
had better concordance with the EWGSOP criteria. This 
was because the FNIH and EWGSOP had similar concep-
tual frameworks and both included measures of lean mass, 
strength, and/or performance. We believe the lack of agree-
ment between these two criteria is explained by differences 
in the participants categorized as having low lean mass: The 
FNIH criteria used ALMBMI, whereas both EWGSOP and 
IWG criteria used ALM/ht2. Although adults with ALM/ht2 
less than 5.67 kg/m2 in women and less than 7.23 kg/m2 in 
men did have low lean mass relative to a young reference 
population, this amount of lean mass was associated with 
faster gait speeds, stronger grip strength, and lower rates 
of obesity compared with participants who had low lean 
mass by ALMBMI. On the other hand, adults who met the 
FNIH criteria for low lean mass (ALMBMI) were slightly 
more impaired with slower walking speeds and lower grip 
strength even though they had higher BMI and ALM, and 
proportionately more obesity. These data suggests that 
ALMBMI, lean mass corrected for body size, is a good dis-
criminator for low lean mass and is likely capturing adults 
who were unable to generate enough strength or function 
relative to their body size (sarcopenic obesity), and ALMBMI 
may be a good measure for low muscle quality or efficiency.
In this study, there were several limitations. In particular, 
the prevalence and agreement rates may have been affected 
by several factors, including (i) the conceptual model, (ii) 
the strength or performance measure and cutpoints used, 
(iii) the method of assessment, and (iv) the study popula-
tion. First, mobility is an important predictor and indicator 
of functional independence and disability. Therefore, our 
conceptual framework and statistical approach was based 
on using mobility impairment as the clinically relevant 
functional state to determine meaningful weakness and 
low lean mass. In this series, we provided two different 
possible FNIH criteria: (i) weakness + low lean mass or 
(ii) slowness + weakness + low lean mass. Although this 
framework resulted in a low prevalence of sarcopenia, we 
chose to combine gait speed with grip strength and lean 
mass because the goal of the FNIH Sarcopenia Project was 
to develop criteria that were conservative with few false 
positives in order to identify individuals who were clearly 
abnormal. Second, there were many different measures of 
strength or performance that could have been used (eg, grip 
strength, leg power, dynamic leg strength, short physical per-
formance, gait speed, and chair stand). However, we chose 
gait speed as a measure of mobility because it was avail-
able in all but one of the pooled studies, it has been reliably 
measured in clinical studies, and has been closely linked 
to function. Additionally, we chose gait speed less than or 
equal to 0.8 m/s because it has been associated with survival 
(36), and the prevalence of gait speed less than or equal to 
0.6 m/s was very rare in our pooled sample. In one study, 
among 70- to 80-year-old Finnish women, the prevalence 
of sarcopenia was 2.7% vs. 0.9% when gait speed less than   
1.0 m/s was used instead of gait speed less than 0.8 m/s 
(28). We chose grip strength as a measure for muscle 
strength because it is easy to use in both clinical and com-
munity settings and was available across all of the studies 
participating. Selection of other measures like short physi-
cal performance battery or chair stand could have increased 
or decreased the prevalence. However, among the partici-
pating studies that had chair stands in our pooled data set, 
the proportion of participants unable to complete a chair 
stand was similar to the proportion with gait speed less 
than or equal to 0.8 m/s. Since the EWGSOP consensus 
statement recommended several different cutpoints for dif-
ferent measures and did not mandate specific measures or 
cutpoints, the prevalence of sarcopenia using the EWGSOP 
criteria could have been influenced by our operational 
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EWGSOP and IWG criteria have reported different preva-
lence rates. For example, Landi and coworkers used the 
lowest tertile of skin fold thickness for low lean mass, the 
prevalence was 21.8% among Italians aged 80–85 years 
(29). In another study, among 103 community-dwelling 
men in the UK Hertfordshire Sarcopenia Study, the preva-
lence for sarcopenia was 6.8% and 7.8% when the lowest 
tertile of DXA-based lean mass was used instead of the 
lowest tertile of skin fold–based fat free mass, respectively 
(27). Furthermore, the positive percent agreement between 
the FNIH and EWGSOP are likely overestimated because 
we used similar gait speeds (<0.8 m/s) and grip strength 
cutpoints (<26 vs <30 kg in men and <16 vs <20  kg in 
women). Third, different brands/methods of DXA were 
used in the studies participating in the FNIH Sarcopenia 
Project, and therefore potential bias may lead to different 
results. However, we tried to account for these differences 
between studies by using a random effects term in all our 
analyses that evaluated the association between our defini-
tions and outcomes.
Finally, the FNIH Sarcopenia Project pooled data sets 
from nine different studies for pooled analyses—the larg-
est to ever be studied in this area and are generalizable 
because the data set had broad representation of commu-
nity-dwelling older adults. However, the pooled data set 
included primarily healthy community-dwelling popula-
tions with few comorbidities. This prevalence may be lower 
compared with more vulnerable populations (eg, assisted 
living, nursing home, or hospitalized adults), where disabil-
ity rates are higher. However, these vulnerable populations 
are more heterogenous, and the factors contributing to slow 
gait are more numerous including cognition, osteoarthritis, 
pain, disuse atrophy, and cachexia. Whether the relationship 
between lean mass, strength, and mobility are the same in 
more vulnerable populations is not known.
This large variation in the prevalence may lead to dif-
ferent conclusions and implications for treatment. In par-
ticular, it is not clear whether treatment of weakness and 
low lean mass, especially with interventions that only target 
improving muscle strength and mass, in different popula-
tions is beneficial. Thus, the work presented in this series 
is a work in progress, and many more questions and studies 
are needed. However, the FNIH Sarcopenia Project provides 
evidence-based and data-driven cutpoints that will help the 
field come to a consensus on a diagnostic criteria. Future 
studies will need to address whether: (i) the prevalence of 
low lean mass, weakness, and poor physical performance 
with the FNIH criteria is higher among different popula-
tions; (ii) the associations between mass, strength, and 
disability are similar or stronger in more disabled or sick 
populations; (iii) the FNIH criteria is useful in identifying 
participants for clinical trials; and (iv) these criteria allow 
clinicians to recognize and potentially treat this disabling 
condition. We envision that the FNIH criteria for clinically 
relevant weakness and low lean mass might be used to plan 
prevention studies in which older persons with weakness 
and low lean mass, but have not yet developed mobility lim-
itations, would receive interventions designed to reduce the 
incidence or increase the time to onset of mobility impair-
ment. Alternatively, the FNIH criteria for clinically relevant 
slowness with weakness and low lean mass may be used to 
identify candidates who already have mobility impairment, 
weakness, and low lean mass for recruitment in treatment 
studies that may look at outcomes like maintaining inde-
pendence, preventing disability, delaying transitions from 
home to long-term care, quality of life, and/or survival.
In conclusion, the current work taps into the expertise 
in the field and utilizes the largest sample of community-
dwelling older adults to build upon and validate prior 
recommendations. These data provide comparison of the 
different definitions and suggest that the definitions have 
good negative, but poor positive agreement. Thus, future 
studies should examine the predictive validity of these dif-
ferent definitions with important clinical outcomes (eg, 
disability, mortality) among different populations that may 
benefit from the diagnoses of sarcopenia.
Supplementary Material
Supplementary material can be found at: http://biomedgerontology.
oxfordjournals.org/
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